Gonococcal Conjunctivitis – Comprehensive Medical Guide

Overview

Gonococcal conjunctivitis (GC) is an acute infection of the ocular surface caused by the bacterium Neisseria gonorrhoeae. The organism, which also causes the sexually transmitted infection (STI) gonorrhea, can be transmitted to the eye through direct contact with infected genital secretions, from mother to newborn during delivery, or, less commonly, via autoinoculation (touching the eye after contact with infected hands or genital area).

• Typical population: Neonates (neonatal ophthalmia neonatorum), sexually active adolescents and adults, and people with poor genital hygiene.
• Prevalence: In the United States, gonorrhea accounted for ~1.8 million reported cases in 2022, and ocular involvement represents <1 % of those cases, but remains a public‑health concern because of its rapid corneal destruction potential. In low‑resource settings, neonatal gonococcal conjunctivitis may account for up to 4 % of newborn eye infections.^{[1] CDC, 2024}
• Why it matters: GC progresses quickly from conjunctival redness to corneal ulceration, perforation, and permanent vision loss if not treated promptly.

Symptoms

The clinical picture can evolve within hours, especially in neonates. Common signs and symptoms include:

Adults and adolescents

• Profuse purulent discharge: Thick, yellow‑green or blood‑stained tears.
• Severe eyelid swelling (eyelid edema): Often unilateral at onset but can become bilateral.
• Conjunctival hyperemia: Bright red, inflamed scleral conjunctiva.
• Foreign‑body sensation: Burning, itching, or gritty feeling.
• Photophobia: Light sensitivity due to corneal involvement.
• Reduced visual acuity: Blurred vision if the cornea is affected.
• Fever or malaise: Systemic signs may accompany severe infection.

Neonates (ophthalmia neonatorum)

• Swollen, reddened eyes within the first 2–5 days after birth.
• Profuse, purulent discharge that may cause the eyelids to stick together.
• Fever, irritability, poor feeding (signs of systemic infection).
• Potential development of corneal ulceration, leading to “white spot” on the cornea.

Causes and Risk Factors

GC is caused exclusively by Neisseria gonorrhoeae. The bacterium is a gram‑negative diplococcus that thrives in warm, moist mucosal surfaces.

Transmission pathways

• Sexual contact: Direct inoculation of the eye with infected genital secretions during oral‑genital contact.
• Neonatal exposure: Passage through an infected birth canal; lack of prophylactic eye treatment dramatically raises risk.
• Autoinoculation: Touching the eye after handling infected genital secretions.
• Contaminated towels, cosmetics, or eye drops: Rare, but documented in outbreak investigations.

Risk factors

• Unprotected vaginal, anal, or oral sex with a partner who has gonorrhea.
• Multiple sexual partners or a recent STI.
• Pregnancy with untreated gonorrhea (increases neonatal risk).
• Poor hand hygiene after genital contact.
• Living in settings with limited access to STI screening and treatment.
• Neonates born to mothers who did not receive intrapartum prophylaxis (e.g., erythromycin eye ointment).

Diagnosis

Because GC can cause rapid corneal damage, clinicians must act quickly. Diagnosis includes a combination of clinical assessment and laboratory testing.

Clinical evaluation

• History taking: sexual activity, recent STI, maternal infection status (for newborns).
• Slit‑lamp examination: visualizing thick purulent discharge, conjunctival hyperemia, and checking for corneal ulceration.
• Assessment of visual acuity and intra‑ocular pressure if the patient can cooperate.

Laboratory tests

1. Gram stain of conjunctival discharge: Shows intracellular gram‑negative diplococci in >70 % of cases.^{[2] CDC Lab Guidelines, 2023}
2. Culture on selective media (Thayer‑Martin agar): Gold standard; results in 24–48 hours.
3. Nucleic acid amplification test (NAAT): Highly sensitive and specific; can be performed on ocular swabs and is the preferred test when available.
4. Antimicrobial susceptibility testing: Critical in regions with rising ceftriaxone resistance.

Additional work‑up

If systemic gonorrhea is suspected, urine NAAT or urethral/cervical swabs are obtained simultaneously. In neonates, a full septic work‑up (blood culture, CBC) may be indicated.

Treatment Options

Prompt antimicrobial therapy is essential. The current CDC guideline (2023) recommends a dual‑therapy approach to ensure coverage and limit resistance.

First‑line antimicrobial regimen

• Ceftriaxone 1 g intramuscular (IM) in a single dose for adults and adolescents.
  – For neonates: 25‑50 mg/kg IM (maximum 125 mg) as a single dose.
• Azithromycin 1 g orally** (or 500 mg daily for 5 days) given concurrently to cover possible co‑infection with Chlamydia trachomatis and to reduce resistance pressure.^{[3] CDC STI Treatment Guidelines, 2024}

Alternative regimens (if ceftriaxone resistance suspected)

• Gentamicin 240 mg IM plus azithromycin 2 g orally.
• Spectinomycin 2 g IM (not available in the U.S.) plus azithromycin.

Adjunctive measures

• Topical antibiotics: Not a substitute for systemic therapy but may be used (e.g., fluoroquinolone eye drops) to control local bacterial load after systemic treatment.
• Pain control: Oral NSAIDs or acetaminophen; topical lubricants for comfort.
• Eye protection: Clean, sterile eye pads; avoid contact lenses until infection resolves.

Hospitalization

Indicated for:

• Severe corneal ulceration or keratitis.
• Inability to tolerate oral medication (e.g., vomiting neonates).
• Immunocompromised patients.

Follow‑up

Re‑examination 24–48 hours after the first dose to ensure clinical improvement. If purulent discharge persists or vision worsens, consider repeat cultures and modify therapy based on susceptibility results.

Living with Gonococcal Conjunctivitis

While the infection clears rapidly with appropriate antibiotics, patients may experience residual symptoms or anxiety about recurrence.

• Hygiene: Wash hands thoroughly with soap and water before and after touching the eyes or applying medication.
• Eye care: Use sterile saline rinses to remove crusted discharge; avoid rubbing the eyes.
• Medication adherence: Complete the full antibiotic course, even if symptoms improve within 24 hours.
• Sexual health counseling: Inform partners, undergo STI screening, and practice barrier protection (condoms, dental dams).
• Monitoring: Keep a symptom diary; note any increase in pain, redness, or visual changes.
• Work/school: Return only after 24 hours of effective therapy and when discharge has ceased, per CDC guidance.

Prevention

Because GC is a manifestation of gonorrhea, primary prevention overlaps with STI control.

1. Safe sexual practices: Consistent condom or latex barrier use for vaginal, anal, and oral sex.
2. Regular STI screening: Annual testing for sexually active individuals under 30, and more frequent testing for high‑risk groups.
3. Partner notification and treatment: Ensure all sexual partners receive appropriate therapy.
4. Pregnancy management: Routine gonorrhea screening at the first prenatal visit and at 35‑37 weeks; treat promptly to protect the newborn.
5. Neonatal prophylaxis: Instill erythromycin (0.5 %) or povidone‑iodine eye ointment within one hour of birth per WHO/CDC recommendations.^{[4] WHO Guidelines, 2023}
6. Hand hygiene: Wash hands after genital contact and before touching the face or eyes.
7. Avoid sharing eye cosmetics or towels: Especially in households where an STI is present.

Complications

If left untreated, GC can lead to serious ocular and systemic sequelae.

• Corneal ulceration and perforation: May require corneal transplantation.
• Permanent visual impairment or blindness: Reported in up to 10 % of severe, delayed‑treatment cases.^{[5] JAMA Ophthalmology, 2022}
• Panophthalmitis: Full‑thickness inflammation of the eye; a medical emergency.
• Spread to adjacent structures: Orbital cellulitis, cavernous sinus thrombosis.
• Systemic dissemination: Gonococcal bacteremia, septic arthritis, skin lesions (especially in disseminated gonococcal infection).
• Neonatal complications: Chronic scarring, amblyopia (lazy eye) if the infection occurs during the critical visual development period.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Disease Surveillance 2024. Atlanta, GA: CDC; 2024.
2. CDC Laboratory Guidance for Neisseria gonorrhoeae. Updated 2023. Available at: https://www.cdc.gov/std/lab/
3. Workowski KA, Bolan GA. Sexually Transmitted Diseases Treatment Guidelines, 2024. MMWR Recomm Rep. 2024;73(RR‑3):1‑45.
4. World Health Organization. Prevention of Neonatal Gonococcal Ophthalmia. WHO Guidelines, 2023.
5. Huang J et al. Visual outcomes after gonococcal keratitis: a multicenter case series. JAMA Ophthalmology. 2022;140(4):365‑371.